Sinew Pharma Inc. (TPEX:6634)

Sinew Pharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	32.58	25.27	41.39	166.81	246.68	551.17
Short-Term Investments	962.69	1,027	1,118	1,109	1,144	931.49
Cash & Short-Term Investments	995.27	1,052	1,159	1,275	1,391	1,483
Cash Growth	-9.79%	-9.22%	-9.13%	-8.31%	-6.17%	338.25%
Accounts Receivable	-	0.05	-	-	-	-
Other Receivables	24.95	24.05	21.43	18.87	16.3	14.3
Receivables	24.95	24.1	21.43	18.87	16.3	14.3
Prepaid Expenses	1.77	1.16	0.78	0.52	0.63	4.22
Other Current Assets	-	-	-	0.57	-	-
Total Current Assets	1,022	1,077	1,181	1,295	1,408	1,501
Property, Plant & Equipment	13.69	17.05	7.12	18.86	14.35	4.51
Other Intangible Assets	14.54	15.44	22.27	38.51	55.58	67.23
Other Long-Term Assets	17.13	17.69	15.46	10.55	9.15	11.84
Total Assets	1,067	1,128	1,226	1,363	1,487	1,585

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	11.95	16.06	18.33	22.9	15.36	10.56
Current Portion of Leases	6.19	5.97	2.82	6.46	2.99	1.05
Current Unearned Revenue	0.52	0.52	0.52	0.52	0.52	0.85
Other Current Liabilities	3.35	2.94	5.52	5.31	4.38	2.65
Total Current Liabilities	22.01	25.49	27.18	35.19	23.25	15.11
Long-Term Leases	6.08	9.23	-	2.82	4.56	-
Other Long-Term Liabilities	1.7	1.7	1.7	1.7	0.85	0.85
Total Liabilities	29.79	36.42	28.88	39.71	28.66	15.96

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	712.89	712.89	713.15	711.66	697.72	690.09
Additional Paid-In Capital	830.51	826.12	816.47	808.87	900.96	1,067
Retained Earnings	-505.13	-445.04	-321.29	-170.92	-140.18	-188.43
Comprehensive Income & Other	-0.72	-2.8	-11.07	-25.95	-	0.43
Shareholders' Equity	1,038	1,091	1,197	1,324	1,459	1,569
Total Liabilities & Equity	1,067	1,128	1,226	1,363	1,487	1,585

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	12.27	15.21	2.82	9.28	7.55	1.05
Net Cash (Debt)	983	1,037	1,156	1,266	1,384	1,482
Net Cash Growth	-9.43%	-10.32%	-8.68%	-8.48%	-6.61%	342.31%
Net Cash Per Share	13.79	14.59	16.21	17.97	19.97	24.90
Filing Date Shares Outstanding	71.29	71.29	71.31	71.17	69.77	69.01
Total Common Shares Outstanding	71.29	71.29	71.31	71.17	69.77	69.01
Working Capital	999.98	1,052	1,154	1,260	1,385	1,486
Book Value Per Share	14.55	15.31	16.79	18.60	20.90	22.73
Tangible Book Value	1,023	1,076	1,175	1,285	1,403	1,502
Tangible Book Value Per Share	14.35	15.09	16.48	18.06	20.11	21.76
Machinery	13.4	13.4	12.93	12.75	7.11	5.83
Leasehold Improvements	11.28	11.28	11.28	11.28	9.31	4.96

Data Source: S&P Global Market Intelligence Last updated: Aug 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 5, 2026

Data Sources Report a data error